Search
MD-0727
go.drugbank.com/drugs/DB05948InvestigationalMD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.
Human thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalHuman thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting. Thrombin is a highly specific serine protease encoded by the F2 gene that transforms soluble fibrinogen into inso...
Mixtures: EVICEL Fibrin Sealant (Human) Solution, 50-90 mg/ml, 800-1200 IU/ml, EVICEL® SELLANTE DE FIBRINA HUMANAElbasvir
go.drugbank.com/drugs/DB11574ApprovedHCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, affecting 72% of all chronic HCV patients.
Mixtures: ZEPATIER 50 MG/100 MG FİLM KAPLI TABLET, 28 ADETPork collagen
go.drugbank.com/drugs/DB14100ApprovedPork Collagen is used within MACI® (autologous cultured chondrocytes on porcine collagen membrane) as an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defect...
Mixtures: Le-Blen Nano Collagen Peptide Serum, P3 RgBromothalonil
go.drugbank.com/drugs/DB14199ApprovedSensitivity to Bromothalonil may be identified with a clinical patch test. … In 2005, MDBGN was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].
Nitrogen
go.drugbank.com/drugs/DB09152ApprovedInvestigationalVet approvedNitrogen is a chemical element with symbol N and atomic number 7. At room temperature, it is a transparent, odorless diatomic gas.
Mixtures: Co-NE-O2-N2 Mixture, Co-HE-O2-N2 MixtureCryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.
PF-06273340
go.drugbank.com/drugs/DB12269InvestigationalYears (Group 1) and Aged 56-75 Years (Group 2)). … investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55